Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-04-11
1997-12-23
Bernhardt, Emily
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
544385, A61K 31495, C07D24108
Patent
active
057008043
DESCRIPTION:
BRIEF SUMMARY
This application is a 35 USC 371 of PCT/GB93/01734 filed Aug. 6, 1993.
The present invention relates to compounds useful as inhibitors of plasminogen activator inhibitor (PAI), to their preparation and to pharmaceutical and veterinary compositions containing them.
Plasminogen activators (PAs) are serine proteases which control the activation of the zymogen, plasminogen, to the active enzyme plasmin. Plasmin is important in a number of physiological and pathological processes including fibrinolysis, tissue remodelling, tumour growth and metastasis. The glycoprotein plasminogen activator inhibitor (PAI) is an endogenous fast-acting inhibitor of PA activity. PAI is a member of the serpin family and is synthesised by a variety of cells including endothelial cells. An imbalance between PAs and PAI contributes to a number of pathological conditions including haemostasis, inflammation, tumour growth and metastasis.
The present invention provides the use of a diketopiperazine of formula (A): ##STR2## wherein each of R.sub.1 to R.sub.10, which may be the same or different, is independently selected from hydrogen, C.sub.1 -C.sub.6 alkyl unsubstituted or substituted by one or more halogen atoms, C.sub.1 -C.sub.6 alkoxy, C.sub.1 -C.sub.6 alkylthio, halogen, hydroxy, nitro, optionally substituted phenyl, cyano, --CH.sub.2 OH, --CH.sub.2 COOH, --CO.sub.2 R.sup.11, --NHCOR.sup.11, --NHSO.sub.2 R.sup.13, --SO.sub.2 R.sup.13, --CON(R.sup.11 R.sup.12), --SOR.sup.13, --SO.sub.2 N(R.sup.11 R.sup.12), --N(R.sup.11 R.sup.12), --O(CH.sub.2).sub.n N(R.sup.11 R.sup.12), --O(CH.sub.2).sub.n CO.sub.2 R.sup.11, --OCOR.sup.11, --CH.sub.2 OCOR.sup.11, --CH.sub.2 NHCOR.sup.11, --CH.sub.2 NHCOOR.sup.13, --CH.sub.2 SR.sup.11, --CH.sub.2 SCOR.sup.11, --CH.sub.2 S(O).sub.m R.sup.13 wherein m is 1 or 2, --CH.sub.2 NHCO(CH.sub.2).sub.n CO.sub.2 R.sup.11, --N(R.sup.11)COR.sup.12, --NHCOCF.sub.3, --NHCO(CH.sub.2).sub.n CO.sub.2 R.sup.11, --NHCO(CH.sub.2).sub.n OCOR.sup.11 and --NHCO(CH.sub.2).sub.n OR.sup.11 wherein n is 0 or is an integer of from 1 to 6, each of R.sup.11 and R.sup.12 is independently H or C.sub.1 -C.sub.6 alkyl and R.sup.13 is C.sub.1 -C.sub.6 alkyl; or any of R.sub.1 and R.sub.2, R.sub.2 and R.sub.3, R.sub.3 and R.sub.4 and R.sub.4 and R.sub.5, or R.sub.6 and R.sub.7, R.sub.7 and R.sub.8, R.sub.8 and R.sub.9 and R.sub.9 and R.sub.10, form together with the carbon atoms to which they are attached a benzene ring which is optionally substituted; or a pharmaceutically acceptable salt or ester thereof; in the manufacture of a medicament for use as an inhibitor of plasminogen activator inhibitor.
The numerals 1 to 10 denote ring positions on the phenyl groups in formula A. The letters a and b refer to the two phenyl rings themselves.
When any two adjacent groups of R.sub.1 to R.sub.10 form, together with the carbon atoms to which they are attached, a benzene ring, that ring is either unsubstituted or it may be substituted by any of the options specified above for R.sub.1 to R.sub.10. The benzene ring forms, together with ring a or b respectively, an optionally substituted naphthalene ring structure.
When ring a or b is substituted phenyl, the benzene ring may be substituted at any of the ortho, meta and para positions by one or more substituents, for example one, two or three substituents, which may be the same or different, independently selected from the groups specified above for R.sub.1 to R.sub.10 other than hydrogen.
A C.sub.1 -C.sub.6 alkyl group is typically a C.sub.1 -C.sub.4 alkyl group, for example a methyl, ethyl, propyl, i-propyl, n-butyl, sec-butyl or tert-butyl group. A halogen is, for example, fluorine, chlorine, bromine or iodine. A C.sub.1 -C.sub.6 alkyl group substituted by halogen may be substituted by 1, 2 or 3 halogen atoms. It may be a perhaloalkyl group, for example trifluoromethyl.
A C.sub.1 -C.sub.6 alkoxy group is typically a C.sub.1 -C.sub.4 alkoxy group, for example a methoxy, ethoxy, propoxy, i-propoxy, n-butoxy, sec-butoxy or tert-butoxy group. A C.sub.1 -C.sub.6 alkylthio group is typically a C.sub.1
REFERENCES:
Chemical Abstracts, vol. 117, No. 28, 1992, Columbus, Ohio, US; abstract No. 90238v, DU Zhengming et al.
Tetrahedron, (Incl. Tetrahedron Reports) vol. 47, No. 30, 1991, Oxford G B pp. 5643-5663, Th. T. Shawe et al.
Chemical Abstracts, vol. 98, No. 28, 1983, Columbus, Ohio US; abstract No. 160674.sub.z Ian RAE et al.
Chemical Abstracts, vol. 97, No. 6, 1982, Columbus, Ohio, US; Abstract No. 40323 p. 70; Ricoh Co.
Yokoi et al, "Neihumicin, a new cytotoxic . . . ", J. Antibiotics vol. XLI No. 4 (494-501, 1988).
Shin et al, "Stereoselective systhesis . . . ", Heterocycles vol. 20 No. 7 1983, 1407-1433.
Marcuccio et al, "Pyrazine Chemistry . . . ", Aust. J. Chem 1984, 37, 1791-4.
Chem. Soc. Jpn, 59, 3917-3923 (1986), Shin et al.
Chemical Abstracts Registry printout of compounds disclosed in Du et al, Chem, Abs vol. 117, No. 28 (1992), 90238v (of record).
Bahner et al, J. Med. Chem. vol. 7 p. 821 (1964).
Bahner et al, Chemical Abstracts, vol. 62. No. 2775f (1964).
Augustin, Chemical Abstracts, vol. 65, No. 16969 a-f (1966).
Shin, Kogaku Kenkyusho Shoho, 3, pp. 9-23 (1980).
Drug Evaluations by American Medical Association, pp. 745-746 (1993).
Wu et al, Chemical Abstracts, vol. 113, No. 17408 (1990).
Kamel et al, Journal of Antibiotics, vol. XLIII pp. 1018-1020 (1990).
Shin et al, J.C.S. Perkin Transactions I pp. 419-420 (1980).
Gallina et al, Tetrahedron 30, pp. 667-673 (1974).
Brocchini Stephen James
Bryans Justin Stephen
Chicarelli-Robinson Maria Ines
Collins Mark Anthony David
Latham Christopher John
Bernhardt Emily
Xenova Limited
LandOfFree
Pharmaceutical compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1802927